- Scott Alexander on googling for Ivermectin and not finding that India has approved its use on a massive scale.
- "Lastly, what I found interesting and troubling was the removal of 30years of publications from PubMed, Lancet, NewEnglandJournal etc. regarding the use of treatments, which I had previously read as I had made investments in my former life in Biotech VC into a company overlapping into the Quinine/Chloroquine/Hydrochloroquine space and another which I sold to Sanofi which used Ivermectin in high concentration in hair cream (suspended in olive oil) for the highly effective treatment of lice (it’ll kill the eggs too) and we researched the hell out of both of these meds, as the use case included the once heralded pediatrics space (5-12 year olds) where the hippocratic oath was taken very seriously. Beyond the removal of the Meds, the barring of their use by knowledgable physicians and their patients using the physicians regulatory bodies, and the barring of filling scrips by the pharmacy regulatory groups and associations. " (2021, NOvember)
- "Update on ivermectin for covid-19," Sebastian Rushworth (April 2021).
There is one thing that is rather odd with this study, and that is that the study authors were receiving payments from Sanofi-Pasteur, Glaxo-Smith-Kline, Janssen, Merck, and Gilead while conducting the study. Gilead makes remdesivir. Merck is developing two expensive new drugs to treat covid-19. Janssen, Glaxo-Smith-Kline, and Sanofi-Pasteur are all developers of covid vaccines. In other words, the authors of the study were receiving funding from companies that own drugs that are direct competitors to ivermectin. One might call this a conflict of interest, and wonder whether the goal of the study was to show a lack of benefit. It’s definitely a little bit suspicious...
This study is yet another one of those many studies that will not be able to show a meaningful effect on hard end points like hospitalization and death. It is a bit strange that studies keep being done on young healthy people who are at virtually zero risk from covid-19, rather than on the multi-morbid elderly, who are the ones we actually need an effective treatment for.